Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
-
Article
Open AccessSPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
SPARC is a matricellular glycoprotein with growth-inhibitory and antiangiogenic activity in some cell types. The study of this protein in hematopoietic malignancies led to conflicting reports about its role as...